SDZ 811

Drug Profile

SDZ 811

Alternative Names: NIM-811; SDZ-NIM-811

Latest Information Update: 19 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antivirals
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C; HIV-1 infections

Most Recent Events

  • 30 Apr 2011 Novartis completes a phase II trial in Hepatitis C in USA, Australia, Belgium, Germany, Puerto Rico, Italy, Netherlands, Spain and Taiwan (NCT00983060)
  • 31 Mar 2011 Efficacy data from a phase I/II trial in Hepatitis C released by Novartis
  • 30 Sep 2009 Phase-II clinical trials in Hepatitis C in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top